XIAOMI-W
01810
POP MART
09992
BABA-W
09988
4
MEITUAN-W
03690
5
HORIZONROBOT-W
09660
HK Stock MarketDetailed Quotes
03681 SINOMAB BIO-B
- 1.550
- -0.010-0.64%
Noon Break Apr 30 11:59 CST
1.69BMarket Cap-8.47P/E (TTM)
1.620High1.540Low586.20KVolume1.560Open1.560Pre Close931.48KTurnover0.05%Turnover RatioLossP/E (Static)1.09BShares1.93052wk High8.12P/B1.69BFloat Cap0.80052wk Low--Dividend TTM1.09BShs Float7.300Historical High--Dividend LFY5.13%Amplitude0.800Historical Low1.589Avg Price300Lot Size--Div YieldTTM--Div Yield LFY
SINOMAB BIO-B News
Hong Kong stocks fluctuated | SINOMAB BIO-B (03681) surged over 34% as the clinical data for the SM17 Concept validation exceeded expectations.
SINOMAB BIO-B (03681) surged over 34%, as of the time of writing, up 31.11%, priced at 1.77 Hong Kong dollars, with a transaction amount of 6.3841 million Hong Kong dollars.
SINOMAB BIO-B: Annual Report 2024
SinoMab's SM17 Dermatitis Drug Achieves Endpoints in Phase 1B China Clinical Trial
The validation clinical data of the SM17 Concept exceeded expectations, highlighting the Global growth potential of SINOMAB BIO-B (03681) in the AD field.
SM17 demonstrates differentiated advantages in rapid itching relief, treatment of skin lesions, and safety compared to existing products on the market.
Sinomab Bioscience Narrows 2024 Loss to 185.1 Million Yuan, Revenue Rises to 2.03 Million Yuan
SINOMAB BIO-B (03681.HK) reduced its annual loss to 0.185 billion yuan.
Gelonghui, March 31丨SINOMAB BIO-B (03681.HK) issued an announcement, as of December 31, 2024 and 2023, the company incurred R&D costs of approximately RMB 94.8 million and RMB 135.4 million, respectively. The annual loss decreased by RMB 58 million, from RMB 243.1 million in the previous year to RMB 185.1 million for the current year, mainly due to (i) the acceptance of the BLA for Suciraslimab in September 2023 and starting from November 2023 in China.
Express News | SinoMab BioScience FY Net Income RMB -185.1 Million
SINOMAB BIO-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2024; ANDCHANGE IN USE OF PROCEEDS
SINOMAB BIO-B (03681.HK) intends to hold a Board of Directors meeting on March 31 to approve the annual performance.
Gelonghui reported on March 19 that SINOMAB BIO-B (03681.HK) announced that a Board of Directors meeting is scheduled for March 31, 2025 (Monday) to consider and approve the Group's full-year performance for the year ending December 31, 2024, and its release, as well as to address Other matters.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
China Antibody-B (03681) and New Brightness-B (01952) have made progress in authorized cooperation, and the new BTK inhibitor SN1011 has achieved positive results in the phase 1b/2a clinical trial interim data.
This milestone result not only recognizes the huge potential of SN1011, but also marks an important milestone achievement in the authorized cooperation agreement between China Antibody and Yunding Xinyao.
China Antibody-B (03681.HK) granted 10.0624 million share options to director Wang Shanchun.
Granolith November 11th | China Antibody-B (03681.HK) announced that on November 11, 2024, the company has granted Wang Shanchun, an executive director, 10.0624 million share options under its share purchase plan, for subscription of a total of 10.0624 million new company shares.
China antibody-B (03681): Director Liu Wenyi resigns as non-executive director
China Antibody-B (03681) announced that Liu Wenyi has resigned as a non-executive director, effective September 2024...
SINOMAB BIO-B: Interim Report 2024
Some biomedical stocks rise, Akeso (09926) rises 13.9%, institutions indicate that the sector's fundamentals are gradually bottoming out and stabilizing.
Golden Finance News | Some biomedical stocks rose, with Akeso (09926) up 13.9%, Sanpower Medical (02257) up 5.47%, China Antibody (03681) up 4.35%, GL Pharm (01672) up 4.12%, Viva Biotech (01873) up 3.45%, Wuxi AppTec (02359) up 2.6%, Wuxi Bio (02269) up 1.27%. China Post Securities expressed that the overall revenue growth rate of the biomedical sector compared to the same period last year is -1.26%, lower than Q1 growth rate, mainly due to vaccines (-32.75%), and CXO (-9.45%).
Have Insiders Sold SinoMab BioScience Shares Recently?
SinoMab BioScience's H1 Loss Narrows as Revenue Rises; Shares Fall 15%